← Leaderboards
Hiep T Tran
Rockland Immunochemicals, Inc.
$7,949,125
Attributed
$7,949,125
Total exposure
20
Grants
20
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.2M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,949,125 · 20
By mechanism
R43$3,421,111 · 13
R44$3,328,339 · 2
N43$899,676 · 4
N01$299,999 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Antibodies”
- Lawrence Corey · Fred Hutchinson Cancer Center$525,765,536
- Bambra Strokes · Ppd Development Lp$461,655,950
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$385,009,925
- Barton F Haynes · Duke University$372,611,596
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$323,573,074
- Dennis R. Burton · Scripps Research Institute$306,733,901
Research focus
AntibodiesCellsProteinsBaseAnimalsProductionAntibody FormationAntigensValidationAffinityLibrariesYeastsIn VitroSpecificitySurfaceGenerationsAnimal ModelTechnologyImmunoglobulin GCatalytic AntibodiesIn VivoEnzyme-Linked Immunosorbent AssayCollaborationsBinding
Grant awards (24)
Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases$826,067
R44 · FY2025 · EY · contact PI
Multi-specific long-acting antibodies for the treatment of retinal neovascular diseases$831,927
R44 · FY2024 · EY · contact PI
Novel immune-escape uricase for treatment of hyperuricemia$299,999
R43 · FY2023 · AI · contact PI
Brain-cell penetrating antibodies for treatment of progressive multiple sclerosis$399,107
R43 · FY2021 · NS · contact PI
Antibody Fragments to Improve HIV gp120 Protein Production$299,815
N43 · FY2019 · AI · contact PI
Pemphigus-specific T cell engagers for pemphigus targeted immunotherapy$280,352
R43 · FY2019 · AI · contact PI
Monoclonal Antibodies to RNA-modifications$299,999
N01 · FY2018 · CA · contact PI
High throughput camelid antibody screening as a drug discovery platform$170,345
R44 · FY2018 · GM · contact PI
High throughput camelid antibody screening as a drug discovery platform$749,787
R44 · FY2017 · GM · contact PI
Modular antibody engineering to overcome the blood brain barrier$236,646
R43 · FY2017 · NS · contact PI
Development Of Arginine Linkage-Specific Antibodies$224,926
R43 · FY2017 · GM · contact PI
High throughput camelid antibody screening as a drug discovery platform$750,213
R44 · FY2016 · GM · contact PI
Hybridoma-free multiplex approach for accelerating mouse monoclonal antibody generation$39,966
R43 · FY2016 · CA · contact PI
Nanobodies for topical delivery to inhibit abnormal choroidal angiogenesis$224,935
R43 · FY2015 · EY · contact PI
High throughput approach for generating human monoclonal antibodies$224,799
R43 · FY2015 · GM · contact PI
Hybridoma free multiplex approach for accelerating mouse monoclonal antibody generation$224,781
R43 · FY2015 · CA · contact PI
Nanobodies for detecting and manipulating A to I editing enzymes and their modified RNA products$224,975
R43 · FY2014 · DA · contact PI
Novel bispecific T cell engaging antibodies for treatment of Lyme disease$224,849
R43 · FY2014 · AI · contact PI
High throughput camelid antibody screening as drug discovery platform$218,085
R43 · FY2014 · GM · contact PI
Human Proteolytic Beta-Amyloid Specific Antibodies for Treatment of Alzheimers Di$282,519
R43 · FY2011 · AG · contact PI
TAS::75 0849::TAS THE CONTRACTOR WILL UTILIZE THE MAMMALIAN EXPRESSION SYSTEM ($299,954
N43 · FY2010 · CA · contact PI
TAS::75 0849::TAS MULTIPLEXED ASSAYS FOR AKT/M TOR PATHWAY - PHASE I SBIR TOPIC$149,937
N43 · FY2010 · CA · contact PI
Novel Point-of-Care Multiplex Lyme Disease Test$315,172
R43 · FY2009 · AI · contact PI
Development of Molecular Pharmacodynamic Assays for Targeted Therapies$149,970
N43 · FY2009 · CA · contact PI